Drug and alcohol dependence · 2014
Serum brain-derived neurotrophic factor and nerve growth factor decreased in chronic ketamine abusers.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ke Xiaoyin, Ding Yi, Xu Ke, He Hongbo, Zhang Minling, Wang Daping, Deng Xuefeng, Zhang Xifan, Zhou Chao, Liu Yuping, Ning Yuping, Fan Ni
Аннотация
AIMS: This study investigated the serum levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in a group of chronic ketamine abusers in comparison to healthy controls. The correlations between the serum BDNF, NGF level with the subjects' demographic, pattern of ketamine use were also examined.
METHODS: 93 subjects who met the criteria of ketamine dependence and 39 healthy subjects were recruited. Serum BDNF and NGF levels were assayed by enzyme-linked immunosorbent assay (ELISA). Psychopathological symptoms were assessed using Positive and Negative Syndrome Scale (PANSS), Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI).
RESULTS: Both serum levels of BDNF and NGF were significant lower in the ketamine users compared to the healthy control subjects (9.50±6.68 versus 14.37±6.07 ng/ml, p=0.019 for BDNF; 1.93±0.80 versus 2.60±1.07 ng/ml, p=0.011 for NGF). BDNF level was negatively associated with current frequency of ketamine use (r=-0.209, p=0.045).
CONCLUSIONS: Both BDNF and NGF serum concentrations were significantly lower among chronic ketamine users than among health controls.
METHODS: 93 subjects who met the criteria of ketamine dependence and 39 healthy subjects were recruited. Serum BDNF and NGF levels were assayed by enzyme-linked immunosorbent assay (ELISA). Psychopathological symptoms were assessed using Positive and Negative Syndrome Scale (PANSS), Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI).
RESULTS: Both serum levels of BDNF and NGF were significant lower in the ketamine users compared to the healthy control subjects (9.50±6.68 versus 14.37±6.07 ng/ml, p=0.019 for BDNF; 1.93±0.80 versus 2.60±1.07 ng/ml, p=0.011 for NGF). BDNF level was negatively associated with current frequency of ketamine use (r=-0.209, p=0.045).
CONCLUSIONS: Both BDNF and NGF serum concentrations were significantly lower among chronic ketamine users than among health controls.